3 Reasons This Recent IPO Is Ready to Take Off

MAV Beauty Brands (TSX:MAV) went public July 10 at $14 a share. It’s yet to trade above its IPO price. That’s about to change.

| More on:
soar high in the sky

MAV Beauty Brands (TSX:MAV) is projecting 25% annual sales growth over the next three years, yet it’s been unable to crack its $14 IPO price since going public July 10.

Marc Anthony Venere, the founder of MAV, has been a hairstylist to some of the biggest stars including Eva Longoria, as well as running his hair salon, but the personal care products have taken him to where he is today — the CEO of a business that’s projected to generate US$160 million in annual revenue by 2020.

Before MAV Beauty went public, I discussed the five things investors needed to understand before buying its stock.

While I liked the idea of a Canadian beauty products business going public, I thought investors were better off buying Estee Lauder (NYSE:EL) at four times sales than paying six times sales for a company that’s not nearly as established.

That said, I was thinking of the average investor who can’t afford to lose their investment, but if you’re an aggressive investor who doesn’t mind a little risk, MAV stock isn’t a terrible bet.

Here are three reasons why.

U.S. expansion should do wonders

One of MAV Beauty’s strategies for growth is to conquer the U.S. market. And while many investors snicker whenever a Canadian company proclaims it’s going to take Manhattan so to speak, I think the company’s plan is a good one.

MAV Beauty has three major brands: Marc Anthony (the original), Cake and Renpure (acquisitions). Right now in the U.S., MAV Beauty has 47 retailers carrying its products. However, 36 of those retailers carry just one of the three brands. Canaccord Genuity Group analyst Camilo Lyon believes getting more of the brands in each of the stores could be worth $36 million in revenue over the next three years.

Of those retailers, 67% of its revenue is from large drug-store chains such as Shoppers Drug Mart in Canada and CVS Health (NYSE:CVS) in the U.S. If MAV can branch out beyond the most obvious candidates, it can build its sales base south of the border.

Innovation is in its DNA

Venere is all about innovation and speed to market. According to the CEO, MAV Beauty gets new products to market in 3-6 months compared to 2-3 years for companies like Estee Lauder.

Millennials and other young consumers want products that are timely and customized to their specific needs. Like the trend to fast fashion, consumers want it now, and if one company can’t meet their needs, they’ll find one that can.

I don’t know if Ulta Beauty sells any of the company’s products yet, but having an innovation mindset should help it gain counter space.

Analysts like it

All five analysts who cover MAV Beauty’s stock have a buy on it with an average 12-month target price of $17.50 with Camilo Lyon giving it a $22 target, 65% higher than where it trades today.

In the second quarter ended June 30, 2018, MAV Beauty had revenue of US$22.9 million, 36% higher than a year earlier; its adjusted profit was US$3.2 million, 35% higher than in the same period a year ago.

Revenues were higher as a result of greater penetration in the North American market. It expects total revenue of US$81.4 million in fiscal 2018, representing 19% growth year over year. On the profit front, it expects adjusted EBITDA of US$27 million in 2018, 10% higher than in 2017.

The verdict on MAV Beauty

I wasn’t ready to recommend MAV stock back in early July, but I’m starting to take a shine to it. If you’ve got some funds set aside for speculative bets that you can afford to lose, MAV Beauty’s stock looks like it’s ready to launch.

 

Fool contributor Will Ashworth has no position in any stocks mentioned.

More on Investing

arrows hit bullseye on target
Dividend Stocks

2 Dividend Stocks That Belong in Almost Every Investor’s Portfolio

These three dividend stocks belong in any investment portfolio.

Read more »

pig shows concept of sustainable investing
Investing

What the Typical 40-Year-Old Canadian Has in Their TFSA and RRSP

Enbridge (TSX:ENB) could be a great play for TFSA and RRSP investors looking to invest more of the cash hoard.

Read more »

diversification and asset allocation are crucial investing concepts
Dividend Stocks

TFSA Income: 2 Dividend Stocks to Hold for the Next 20 Years

These stock should be attractive picks for buy-and-hold dividend investors.

Read more »

Investor reading the newspaper
Dividend Stocks

BCE’s Dividend Has Been Getting a Lot of Attention: Here’s Why

Long-term investors could investigate BCE as an income play with multi-year turnaround potential.

Read more »

data analyze research
Dividend Stocks

TFSA at 60: 2 Dividend Stocks to Help Any Canadian Catch Up

Build a stronger TFSA at 60 with two dependable Canadian dividend stocks offering income, stability, and long-term growth potential.

Read more »

bank of canada governor tiff macklem
Bank Stocks

The Bank of Canada Just Spoke: 2 Canadian Stocks I’d Buy Before Rates Fall Further

With Canadians carrying $1.80 of debt for every after-tax dollar earned, interest rates could shape both borrowers and TSX returns.

Read more »

senior man and woman stretch their legs on yoga mats outside
Retirement

Reaching Retirement: Here’s the Typical TFSA Balance for Canadians Approaching 60

You can build a substantial TFSA as a part of your retirement planning strategy. Start by maximizing your TFSA contributions.

Read more »

man touches brain to show a good idea
Dividend Stocks

2 Dividend Stocks That Look Built for the Rate Pause

These high-quality dividend stocks offer attractive yields, dependable income, and protection against inflation.

Read more »